AI drug developers Recursion, Exscientia to merge

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company.

The new company will continue using the Recursion name and be led by Recursion co-founder and CEO Chris Gibson. Exscientia’s interim CEO, David Hallett, will serve as the company’s science chief. Recursion is spending $688 million in the all-stock deal, Reuters reported.

Recursion shareholders will own approximately 74% of the combined company and Exscientia shareholders will own approximately 26%.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

FDA commissioner calls on House committee to help combat drug shortages

WASHINGTON — FDA Commissioner Robert Califf appeared before the House Oversight Committee on Thursday to plead his case again for more authority to monitor the

April 12, 2024

Q&A: How can the US maintain access to essential drugs? – Pharmaceutical Technology

Out of stock sign board placed in front of medical or pharma store counter – concept of sold out and increase in damand of medicines.

June 29, 2023

Real world data highlights effectiveness of RSV vaccine

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV — short for

October 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.